ProMetic Life Sciences Inc.
TSX : PLI
OTCQX : PFSCF

ProMetic Life Sciences Inc.

December 04, 2014 07:00 ET

ProMetic's PBI-4050 to Target Patients With the Metabolic Syndrome and Associated Type 2 Diabetes

Clinical program to commence in Q4 2014

PBI-4050 to target insulin resistance and loss of pancreatic insulin production, the fundamental mechanisms in type 2 diabetes

LAVAL, QUEBEC--(Marketwired - Dec. 4, 2014) - ProMetic Life Sciences Inc. (TSX:PLI)(OTCQX:PFSCF), ("ProMetic" or the "Corporation") announced today that it is pursuing a clinical program designed to evaluate the benefit of PBI-4050 in patients affected by the metabolic syndrome and resulting Type 2 diabetes. The metabolic syndrome is a major risk factor for cardiovascular disease and for Type 2 diabetes, and consists of the constellation of central (truncal) obesity, high blood triglycerides, low HDL ("good") cholesterol, elevated blood pressure, and elevated blood glucose. Obesity is believed to cause a chronic inflammatory state, which leads to insulin resistance and so may in turn result in cardiovascular disease and/or Type 2 diabetes. Given the global epidemic of obesity, both in the developed and developing world, the metabolic syndrome and its consequences present a devastating public health problem.

"Utilizing proven preclinical models for Type 2 diabetes, our scientists, as well as the team led by Dr. Ray Harris at Vanderbilt University, have clearly demonstrated that administration of PBI-4050 leads to a major reduction in the markers of the inflammatory state in the kidney and pancreas and in insulin resistance", stated Mr. Pierre Laurin, President and Chief Executive Officer of ProMetic. "The Vanderbilt data also confirms the findings of ProMetic scientists, that PBI-4050 has a direct effect on the pancreas itself, and by reducing inflammation and macrophage infiltration preserves insulin production in the islets. This clinical program will enable us to evaluate the ability of PBI-4050 to reverse the inflammatory state and the consequent insulin resistance in patients with the metabolic syndrome and diabetes. It thus complements our other Phase Ib/II study, which is primarily focused on improving the renal function of diabetic patients with chronic kidney disease", added Mr. Laurin.

ProMetic is initiating its metabolic syndrome clinical program this quarter in Canada, and intends to include other already identified sites in the United Kingdom and in the US shortly thereafter. ProMetic also intends to file a request for an Orphan Drug Designation ("ODD") with the US Food and Drug Administration ("FDA") addressing specific sub-populations of patients affected by such syndromes.

"It is difficult to grasp the numbers and the overwhelming public health issues presented by the global epidemic of obesity, the metabolic syndrome, and Type 2 diabetes", said Dr. John Moran, ProMetic's Chief Medical Officer. "The International Diabetes Federation estimates that in 2013 there were 300 million diabetics world-wide, and that that number will increase to 600 million by the year 2035. The Centers for Disease Control estimates that 1 of 3 children born in the U.S. during the year 2000 will develop diabetes during their lifetime. Lifestyle interventions have been largely unsuccessful in slowing the epidemic, and it is our hope that PBI-4050 will - as in the preclinical model - reverse the inflammatory state and resulting insulin resistance and preserve insulin production by the pancreas, the major mechanistic factors in Type 2 diabetes", added Dr. Moran.

ProMetic has successfully completed its PBI-4050 Phase I clinical trial in 40 healthy volunteers, in which it was found to be safe and well tolerated, with no serious adverse events. The Corporation has also started enrolling patients with diabetic kidney disease (DKD).

More on PBI-4050

PBI-4050 is an orally active lead drug candidate with excellent safety and efficacy profiles confirmed in several in vivo experiments targeting fibrosis. Fibrosis is a very complex process by which continuing inflammation causes vital organs to lose their function as normal tissue is replaced by fibrotic scar tissue. The proof of concept data generated to date confirms our lead drug candidates' anti-fibrotic activity in several key organs including the kidneys, the heart, the lungs and the liver. Twenty six million patients in the U.S. alone are diagnosed with chronic kidney diseases ("CKD"). Patients with severe CKD stages (3 and 4) suffer from a gradual and accelerated loss of their renal function (end-stage renal disease or ESRD) leading to the need for hemodialysis. Cardiovascular complications for ESRD patients on hemodialysis are a common cause of death.

About ProMetic Life Sciences Inc.

ProMetic Life Sciences Inc. (www.prometic.com) is a long established biopharmaceutical company with globally recognized expertise in bioseparations, plasma-derived therapeutics and small-molecule drug development. ProMetic offers its state of the art technologies for large-scale purification of biologics, drug development, proteomics and the elimination of pathogens to a growing base of industry leaders and uses its own affinity technology that provides for highly efficient extraction and purification of therapeutic proteins from human plasma in order to develop best-in-class therapeutics and orphan drugs. ProMetic is also active in developing its own novel small-molecule therapeutic products targeting unmet medical needs in the field of fibrosis, anemia, neutropenia, cancer and autoimmune diseases/inflammation as well as certain nephropathies. Headquartered in Laval (Canada), ProMetic has R&D facilities in the UK, the U.S. and Canada, manufacturing facilities in the UK and business development activities in the U.S., Europe and Asia.

Forward Looking Statements

This press release contains forward-looking statements about ProMetic's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, ProMetic's ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of ProMetic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in ProMetic's Annual Information Form for the year ended December 31, 2013, under the heading "Risk and Uncertainties related to ProMetic's business". As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations. All amounts are in Canadian dollars unless indicated otherwise.

Contact Information

  • Pierre Laurin
    President and CEO
    ProMetic Life Sciences Inc.
    +1.450.781.0115
    p.laurin@prometic.com

    Frederic Dumais
    Director, Communications and Investor Relations
    ProMetic Life Sciences Inc.
    +1.450.781.0115
    f.dumais@prometic.com